AFP and hepatocellular carcinoma: Instead, the combination of tumor biomarkers with other methods such as tissue biopsy and endoscopy is a promising alternative to improve the effectiveness of screening.48,49 For example, the combined detection of AFP with cfDNA can improve the specificity of HCC diagnosis to 94.4%, which was superior to that of AFP alone in terms of higher sensitivity and better clinical correlation.50 The advantages of biomarker panels have been confirmed as compared with a single biomarker, especially a panel of biomarkers reflecting changes in independent pathways.